Finally, while Gilead terminated its Phase II study of the investigational monoclonal antibody simtuzumab in patients with idiopathic pulmonary fibrosis (IPF) due to lack of efficacy, Phase II studies of simtuzumab are ongoing in patients with non-alcoholic steatohepatitis (NASH) and primary sclerosing cholangitis (PSC)
The episodic format keeps content fresh, engaging, and evolving over time. You can expect future ads to tout other Ozempic exclusive benefits like being the only FDA-approved GLP-1 that improves blood sugar along with diet and exercise, and reduces the risk of major cardiovascular events. The new ads are running on connected TV, social and digital in lengths including :06, :15, :45 and three minute-plus
WjtowiczMJarekAChajewskaKKwiatkowskaD
may take longer to see results than other methods
Frequently Asked Questions Sources & References Primary: Eli Lilly press release (Dec 11, 2025) TRIUMPH-4 topline